• Something wrong with this record ?

Low potential of circulating interleukin 1 receptor antagonist as a prediction marker for squamous cell carcinoma of the head and neck

L. Boldrup, P. Coates, X. Gu, L. Wang, R. Fåhraeus, T. Wilms, N. Sgaramella, K. Nylander

. 2021 ; 50 (8) : 785-794. [pub] 20210509

Language English Country Denmark

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21025037

Grant support
Lion´s Cancer Research Foundation
Region Västerbotten, Sweden
Cancer Research Foundation in Northern Sweden
00209805 Ministry of Health, Czech Republic
20 0754 PjF 01H Cancerfonden

BACKGROUND: Circulating markers are attractive molecules for prognosis and management of cancer that allow sequential monitoring of patients during and after treatment. Based on previous protein profiling data, circulating interleukin 1 receptor antagonist (IL-1Ra) was evaluated as a potential diagnostic and prognostic marker for squamous cell carcinomas of the head and neck (SCCHN). In this study, we aimed at confirming the clinical relevance of plasma IL-1Ra in SCCHN and exploring its potential as a prediction marker for SCCHN. METHODS: Plasma from 87 patients with SCCHN, control plasma from 28 healthy individuals and pre-diagnostic plasma from 44 patients with squamous cell carcinoma of the oral tongue (SCCOT) and 88 matched controls were analysed with IL-1Ra electrochemiluminescence immunoassays from mesoscale diagnostics. RESULTS: Plasma IL-1Ra was found to be up-regulated in patients with oral tongue, gingiva and base of tongue tumours compared to healthy individuals (p < 0.01). IL-1Ra levels positively correlated with tumour size (p < 0.01) and body mass index (p = 0.013). Comparing pre-diagnostic plasma to the matched controls, similar IL1-Ra levels were seen (p = 0.05). CONCLUSION: The anti-inflammatory cytokine IL-1Ra could be a diagnostic marker for SCCHN, whereas its potential as a cancer prediction marker was not supported by our data.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025037
003      
CZ-PrNML
005      
20211026134202.0
007      
ta
008      
211013s2021 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jop.13187 $2 doi
035    __
$a (PubMed)33880804
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Boldrup, Linda $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
245    10
$a Low potential of circulating interleukin 1 receptor antagonist as a prediction marker for squamous cell carcinoma of the head and neck / $c L. Boldrup, P. Coates, X. Gu, L. Wang, R. Fåhraeus, T. Wilms, N. Sgaramella, K. Nylander
520    9_
$a BACKGROUND: Circulating markers are attractive molecules for prognosis and management of cancer that allow sequential monitoring of patients during and after treatment. Based on previous protein profiling data, circulating interleukin 1 receptor antagonist (IL-1Ra) was evaluated as a potential diagnostic and prognostic marker for squamous cell carcinomas of the head and neck (SCCHN). In this study, we aimed at confirming the clinical relevance of plasma IL-1Ra in SCCHN and exploring its potential as a prediction marker for SCCHN. METHODS: Plasma from 87 patients with SCCHN, control plasma from 28 healthy individuals and pre-diagnostic plasma from 44 patients with squamous cell carcinoma of the oral tongue (SCCOT) and 88 matched controls were analysed with IL-1Ra electrochemiluminescence immunoassays from mesoscale diagnostics. RESULTS: Plasma IL-1Ra was found to be up-regulated in patients with oral tongue, gingiva and base of tongue tumours compared to healthy individuals (p < 0.01). IL-1Ra levels positively correlated with tumour size (p < 0.01) and body mass index (p = 0.013). Comparing pre-diagnostic plasma to the matched controls, similar IL1-Ra levels were seen (p = 0.05). CONCLUSION: The anti-inflammatory cytokine IL-1Ra could be a diagnostic marker for SCCHN, whereas its potential as a cancer prediction marker was not supported by our data.
650    12
$a spinocelulární karcinom $x diagnóza $7 D002294
650    12
$a nádory hlavy a krku $7 D006258
650    _2
$a lidé $7 D006801
650    _2
$a antagonista receptoru pro interleukin 1 $7 D053590
650    _2
$a receptory interleukinu-1 $7 D017472
650    _2
$a dlaždicobuněčné karcinomy hlavy a krku $7 D000077195
655    _2
$a časopisecké články $7 D016428
700    1_
$a Coates, Philip $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Gu, Xiaolian $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
700    1_
$a Wang, Lixiao $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
700    1_
$a Fåhraeus, Robin $u Department of Medical Biosciences, Umeå University, Umeå, Sweden $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Institute of Molecular Genetics, University of Paris St. Louis Hospital, Paris, France
700    1_
$a Wilms, Torben $u Department of Clinical Sciences, Umeå University, Umeå, Sweden
700    1_
$a Sgaramella, Nicola $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
700    1_
$a Nylander, Karin $u Department of Medical Biosciences, Umeå University, Umeå, Sweden
773    0_
$w MED00007685 $t Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology $x 1600-0714 $g Roč. 50, č. 8 (2021), s. 785-794
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33880804 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134208 $b ABA008
999    __
$a ok $b bmc $g 1714198 $s 1145544
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 50 $c 8 $d 785-794 $e 20210509 $i 1600-0714 $m Journal of oral pathology & medicine $n J Oral Pathol Med $x MED00007685
GRA    __
$p Lion´s Cancer Research Foundation
GRA    __
$p Region Västerbotten, Sweden
GRA    __
$p Cancer Research Foundation in Northern Sweden
GRA    __
$a 00209805 $p Ministry of Health, Czech Republic
GRA    __
$a 20 0754 PjF 01H $p Cancerfonden
LZP    __
$a Pubmed-20211013
Back

Find record

Citation metrics

Archiving options